| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5225233 | B | Activation of human recombinant AMPK A2/B2/G1 assessed as increase in AMPK phosphorylation using FL-peptide as substrate incubated for 120 mins by EZ reader method | Homo sapiens | 12 | ALA5223143 | protein complex format | Scientific Literature | |
| 2. | ALA5225234 | B | Activation of AMPK alpha2beta2gamma1 in rat L6 cells assessed as increase in AMPK phosphorylation by ELISA assay | Rattus norvegicus | 4 | ALA5223143 | cell-based format | Scientific Literature | |
| 3. | ALA5225235 | A | Inhibition of CYP1A2 in human liver microsomes using 7-ethoxyresorufin as substrate | Homo sapiens | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 4. | ALA5225236 | A | Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate | Homo sapiens | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 5. | ALA5225237 | A | Inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate | Homo sapiens | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 6. | ALA5225238 | A | Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate | Homo sapiens | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 7. | ALA5225239 | A | Inhibition of CYP3A4 in human liver microsomes using terfenedine as substrate | Homo sapiens | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 8. | ALA5225240 | A | Metabolic stability in human liver microsomes assessed as compound remaining incubated for 30 mins | Homo sapiens | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 9. | ALA5225241 | A | Metabolic stability in rat liver microsomes assessed as compound remaining incubated for 30 mins | Rattus norvegicus | 1 | ALA5223143 | microsome format | Scientific Literature | |
| 10. | ALA5225242 | A | Protein binding in serum (unknown origin) assessed as free fraction by equilibrium dialysis method | Not specified | 1 | ALA5223143 | cell-free format | Scientific Literature | |
| 11. | ALA5225243 | A | Total clearance in rat at 0.5 mg/kg,iv | Rattus norvegicus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 12. | ALA5225244 | A | AUC in rat at 1 mg/kg,po | Rattus norvegicus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 13. | ALA5225245 | A | Cmax in rat at 0.5 mg/kg,iv | Rattus norvegicus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 14. | ALA5225246 | A | Permeability coefficient in rat liver at 0.5 mg/kg,iv | Rattus norvegicus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 15. | ALA5225247 | A | Permeability coefficient in rat muscle tissue at 0.5 mg/kg,iv | Rattus norvegicus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 16. | ALA5225248 | F | Antidiabetic activity against diabetic KKAy mouse model assessed as increase in ACC phosphorylation in skeletal muscle at 0.3 to 3 mg/kg,po bid | Mus musculus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 17. | ALA5225249 | F | Antidiabetic activity against diabetic KKAy mouse model assessed as acute glucose lowering effect at 0.3 to 3 mg/kg,po bid | Mus musculus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 18. | ALA5225250 | F | Antidiabetic activity against diabetic KKAy mouse model assessed as decrease in HbA1c level at 0.3 to 3 mg/kg,po bid observed upto 21 days | Mus musculus | 1 | ALA5223143 | organism-based format | Scientific Literature | |
| 19. | ALA5225251 | F | Antidiabetic activity against diabetic KKAy mouse model assessed as decrease in plasma glucose level at 0.3 to 3 mg/kg,po bid observed upto 21 days | Mus musculus | 1 | ALA5223143 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!